1. Infrastructure to Enable P4 Medicine: Investing in Innovative Personalized Health Solutions OSU Annual Personalized Health Care National ConferenceOctober 6, 2011

2. Why Personalized Health?

3. International Comparison Health Expenditure, 1980–2008 Total expenditures on healthas percent of GDP Average spending on healthper capita ($US PPP) Source: OECD Health Data 2010 (Oct. 2010).

4. An Aging Global Population

5. Number of Practicing Physicians per 1,000 Population, 2008 * 2007. ** 2006. Source: OECD Health Data 2010 (Oct. 2010).

6. Average Annual Growth Rate of Practicing Physicians per 1,000 Population, 1998–2008 Percent * 1997–2007. ** 1996–2006. Source: OECD Health Data 2010 (Oct. 2010).

7. Asthma Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.

8. Diabetes Acute Complications Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.

9. Congestive Heart Failure Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.

10. * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009. Diabetes Lower Extremity Amputation Rates per 100,000 Population Age 15 and Older, 2007*

12. Create deeper engagement with health consumer

13. Provide clear, simple tools to the provider

14. Make it better, cheaper and faster The Big Need The Six Trillion Dollar Man

15. Two Key Innovations of Our Generation Transforming Personalized Health

16. The Physic view of Personalized Health Health is inherently personal and… ...one size does not fit all. Personalized health uses precise tools and technologiesto measure an individual’s unique characteristics to enhance health.

17. Where is Health Being Personalized? Clinical Medicine Drug Development Consumer Products Diagnostics Insurance PBMs Clinical Nutrition Food Safety

18. What Does it Look Like? Clinical Medicine Consumer Products Diagnostics Drug Development Insurance PBMs Clinical Nutrition Food Safety

19. It also looks like this 16

20. And this.. 17

21. And this… 18

22. And this… 19

23. And this.. 20

24. And this.. 21

26. Supported by validated science

27. Actionable result

28. Informs meaningful decision about intervention (treatment/procedure) or behavior

29. Clinically Meaningful

30. Provides significant incremental benefit over use of existing tools

31. Demonstrates near-term benefit or cost-effectiveness

32. Alignment of Patient, Physician and Payer

33. Path to regulatory approval and reimbursement

34. Consumer-centric applicationsOur Criteria

36. Mental Health

37. Cardiovascular Health

38. Reproductive Health

39. Cancer

40. Condition-Specific Nutritional Needs

41. Fitness

44. $11M Series B in 3/11 for PGx analysis of depression and anxiety therapies (Mental Health)

45. $30M Series C in 10/10 for diagnosis of Tissues of Origin (Cancer)

46. $18M Series A in 9/10 for pre-pregnancy screening (Reproductive Health)

47. $13M Series B in 7/11 for POC diagnostics for bloodstream infections (Infectious Disease)

48. $27M Series B in 7/11 for POC diagnostics for STDs (Infectious Disease)

49. $23M Series D in 8/11 for POC diagnostics for candida (Infectious Disease)

50. $18M Series B in 8/11 for inflammatory biomarkers for CVD (Cardiovascular)

51. $18M Series C in 9/11 for inflammatory biomarkers for RA (Autoimmune)VC Money Backing Innovation

52. How do I feel?